Observational study on characteristics and outcomes of patients with surgically removed lung cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients with surgically resected lung cancers in China, utilizing real-world data to analyze treatment patterns and outcomes. It aims to describe patient characteristics, identify trends in treatment, and explore factors associated with overall survival. By leveraging advanced data processing algorithms and ensuring data quality, the study seeks to address emerging clinical questions related to lung cancer treatment. The findings could provide valuable insights into the evolving landscape of lung cancer management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age above 18.
* Have received surgical resection for lung malignancies.

Exclusion Criteria:

* Participants whose data are of low quality, poor completeness or poor internal linkage.

Where it's running

• National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Jie He, MD-PhD — National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS and PUMC
• Study coordinator: Fengwei Tan, MD-PhD
• Email: tanfengwei@126.com
• Phone: +8601087787792

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dose-reduced chemotherapy for lung cancer patients with health issues

  This study is testing if a lower dose of chemotherapy can help lung cancer patients with other health issues feel better and manage their treatment safely.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT05800587

• Evaluating PC14586 for advanced solid tumors with a specific mutation

  This study is testing a new oral medication called PC14586 to see if it can help people with advanced solid tumors that have a specific mutation in the TP53 gene.

  Recruiting at 71 sites Phase 1/2 PMV Pharmaceuticals, Inc · Irvine, California and 75 other locations · NCT04585750

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Does the time of day for PD-1/PD-L1 therapy affect response in NSCLC and HNSCC

  In people with advanced NSCLC or resectable head and neck cancer, this study tests whether receiving PD-1/PD-L1 therapy in the morning versus the afternoon changes treatment outcomes.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07630168

• BL-M14D1 plus atezolizumab vs standard therapy in first-line extensive-stage small cell lung cancer

  A first-line treatment for adults with extensive-stage small cell lung cancer tests whether adding BL-M14D1 to atezolizumab and standard chemotherapy helps more than standard care.

  Recruiting at 7 sites Phase 3 SystImmune Inc. · Springdale, Arkansas and 61 other locations · NCT07625644

• First-in-human test of HH160 in people with advanced solid tumors

  HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.

  Recruiting at 3 sites Phase 1 Huahui Health · Waratah, New South Wales and 2 other locations · NCT07623369

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.